DIRS.INFO The most relevant business & tech news

☆ A 27-year-old investor building a $2 million retirement portfolio in 8 years shares why he's buying a fund that's up 324% since inception and made up of cheap stocks with strong competitive advantages
▼ + stars: | 2023-10-21 | by ( Laila Maidan | ) www.businessinsider.com time to read: +5 min

"You're telling me that the big tech companies are the only reason the stock market, aka the S&P 500, is green? Because at the end of the day, sure, I've got great exposure to the magnificent seven, but I want exposure to companies outside of just these big, big, big tech names." So, he began to look at various ETFs that have outperformed the S&P 500 on three-, five- and 10-year horizons. Meanwhile, the S&P 500 has lagged both since MOAT's launch, at 209%. Portfolio VisualizerPortfolio VisualizerMOAT has a dividend yield of 1.08% compared to the S&P 500, which has a yield of 1.57%.

Persons: Austin Hankwitz, Hankwitz, I've, Morningstar Organizations: Gilead Sciences, Comcast Locations: Gilead

☆ Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.
▼ + stars: | 2023-09-26 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

A Miami man has pleaded guilty in federal court to distributing adulterated HIV drugs dispensed to U.S. patients. A Miami man pleaded guilty to distributing as much as $25 million worth of misbranded and adulterated HIV drugs that were dispensed by pharmacies across the U.S. to unsuspecting patients, federal prosecutors said. Herrera pleaded guilty in U.S. District Court in Miami on Monday to one count of conspiracy to introduce adulterated and misbranded drugs in the U.S. market, court filings show. Prosecutors said the wholesalers were involved in the criminal scheme, but the pharmacies were unaware that the drugs were altered or misbranded. The adulterated and misbranded drugs included Truvada, Biktarvy and other unnamed medications.

Persons: Armando Herrera, Herrera, Prosecutors Organizations: Miami, Gilead Sciences Locations: U.S, Miami, Texas , California, Washington

☆ Opinion: The 2,000-year-old advice for coping in 2023
▼ + stars: | 2023-09-24 | by ( Richard Galant | ) edition.cnn.com time to read: +21 min

We’re looking back at the strongest, smartest opinion takes of the week from CNN and other outlets. A surprising number claimed to think about the ancient empire as often as ‘every day’ or least every week or two. It became a meme (are you even in a relationship if she hasn’t asked you about the Roman Empire? They marvel at their absolute dominion, their mastery of every strand of civilisation — and then how that power suddenly slipped away. Biden on Wednesday took steps to speed up the ability of Venezuelans in the US to obtain work permits.

Persons: CNN —, ”, Lucius Annaeus Seneca, Seneca, Caligula, Claudius, Nero, Bobby McFerrin’s musing, David M, Perry, hasn’t, Jo Ellison, —, Marcus Aurelius, that’s, David Perry, “ There’s, ” Perry, Paula M, Krebs, “, Donald Trump’s, Ron DeSantis, Trump, …, ’, ” Cupp, Roe, Wade, Cupp, he’s, Dean Obeidallah, Trump’s, Patrick T, Brown, Bill Bramhall, Content Agency Rupert Murdoch, Rupert Murdoch, Lachlan Murdoch, David Zurawik, Rupert, Murdoch, Roger Ailes, Richard Nixon, ” Murdoch “, Walt Handelsman, Kevin McCarthy, Max Burns, Donald Trump, today’s MAGA, ” Clay Jones, Chuck Schumer, Elena Sheppard, Sen, John Fetterman, baring, Fetterman, Kim Jong Un, Vladimir Putin, Kim Yo Jong, Sung, Yoon Lee, “ Kim Yo Jong, Kim, Kim Jong, ” “, Hunter Biden isn’t, Alexis Coe, George Washington’s, James Madison, Abraham Lincoln, Teddy Roosevelt, Ronald Reagan, George H.W, Bush, Hunter, … Hunter, Joe Biden, Biden, Peter Bergen, Mike Pence, … Biden, Bergen, ” Lisa Benson, Martin Sheen, Melissa Fitzgerald, Gurney, John F, Melissa, Andy, Michael Bociurkiw, ” Bociurkiw, Volodymyr Zelensky “, Zelensky, Lanhee J, Chen, ” Chen, Keir Giles, It’ll, Jennifer Wexton, Barbara Comstock, Alex Brandon, Jill Filipovic, Democrat “, ” Wexteon “, Eric Adams, Julian Zelizer . Biden, ” Don’t, David Horsey, Agency Frida Ghitis, Agatha Christie, China Adam H, Sobel, Holly Thomas, Russell Brand, Akanksha, Dan Perry, Gilead, Netanyahu government’s, Gene Seymour, Jann, Reggie B, Maren Morris, Matt Winkelmeyer, ” Maren Morris, Nicole Hemmer, Morris ’, Morris, Jason Aldean’s “, Oliver Anthony’s “ Rich, Richmond ”, “ Rich, ” Hemmer, Anthony himself, ‘, Hemmer Organizations: CNN, Financial Times, West Virginia University, Modern Language Association, WVU, West Virginia, Republican, Press, Florida Gov, White, Content Agency, Content Agency Rupert Murdoch Media, Fox News, Capitol, Agency, Democratic, fied Republican Party, Republican Party, Justice Department, Qatari, Amnesty International, Kennedy Center, UN, Assembly, CBS, Ukraine’s, Republicans, Democrat, Progressive Supra, GOP, Walton, Mobile, North, Richmond Locations: Rome, Ukraine, TikTok, Roman, Roman Republic, Washington, ”, Korean, North Korea, Iran, Qatar, Russia, Moscow, Kyiv, Dulles , Virginia, Virginia, New York City, United States, China, Las Vegas , Nevada

But Mintz also acknowledges that having more places to access PrEP likely will not be enough to substantially increase its use in more vulnerable communities. “There needs to be a couple of levers that need to be pulled for everybody to access PrEP who are eligible to access PrEP,” Mintz says. (Joe Raedle/Getty Images)Meanwhile, a pending ruling in a federal appellate court looms as a threat that could more broadly undermine PrEP coverage. “We don’t know what the 5th Circuit could do.”In the wake of the March court ruling, insurers expressed support for preventive services. “Right now, PrEP uptake is quite good among gay white men, but among people of color and among women PrEP access is quite limited,” Dawson says.

Persons: Apretude, ”, Omar Martinez Gonzalez, Sean Bland, we’re, ” Bland, Truvada, ” Martinez Gonzalez, Laura Mintz, Mintz, ” Mintz, Truvada –, AIDSVu, Joe Raedle, Laurie Sobel, “, ” Sobel, Lindsey Dawson, ” Dawson, Torrian Baskerville, Baskerville, ” Baskerville, who’d, Biden, Bland Organizations: U.S . Preventive Services Task Force, U.S . Food, Drug Administration, Affordable, AIDS Foundation Chicago, “, Centers for Disease Control, Santa Clara University School of Law, Georgetown University’s O’Neill Institute for National, Global Health, Blacks, PrEP, Emory University, Gilead Sciences, Black PrEP, Case Western Reserve University School of Medicine, Pride Network of, ViiV Healthcare, GlaxoSmithKline, U.S, Circuit, Appeals, Supreme, Human Rights, Navigators, Department of Health, Human Services Locations: U.S, Black, Cleveland, Gilead, –, Miami, Texas, Ohio

☆ Opinion: The Netanyahu government’s next target: Israel’s free press
▼ + stars: | 2023-09-19 | by ( Dan Perry | Gilead Sher | ) edition.cnn.com time to read: +7 min

A cornerstone of those shared values is both countries’ historic commitments to a free press. Israel’s journalism, as in the United States, is freewheeling and independent, and reporters are famously skeptical and often critical of any government. Gilead Sher Courtesy Gilead SherAs in the United States, Israeli governments have always viewed a free press as inviolate because of the central role it plays in upholding democracy and fostering government transparency and accountability — until now. Missed so far, however, in most mainstream US news, are the government’s initiatives to erode Israel’s free press and gradually turn Israeli media into government propaganda vehicles. And indeed, as already stated, Netanyahu’s government has targeted much more than the free press.

Persons: Dan Perry, Gilead Sher, Ehud Barak, Benjamin Netanyahu, Joe Biden, Netanyahu, Gilead, Biden, Donald Trump, Viktor Orban, Orban, Israel Organizations: London, Associated Press, Israeli, CNN, UN, Assembly, BBC, Israeli Public Broadcasting Corporation, MSNBC, Fox News, Hungarian Locations: Cairo, Europe, Africa, Israel, United States, New York, America

Are higher rates going to lead to some slow down in conjunction with the dwindling of excess consumer savings," said Lefkowitz, who also cited concerns about high valuations in equities. The Dow Jones Industrial Average (.DJI) rose 75.86 points, or 0.22%, to 34,576.59, the S&P 500 (.SPX) gained 6.35 points, or 0.14%, to 4,457.49 and the Nasdaq Composite (.IXIC) added 12.69 points, or 0.09%, to 13,761.53. For the week, which was shortened by Monday's Labor Day holiday, the S&P 500 fell 1.3%, while the Nasdaq lost 1.9% with both snapping two weeks of gains. After losing 2.9% in two sessions, the S&P 500 technology sector (.SPLRCT) closed higher. The S&P 500 posted 13 new 52-week highs and 17 new lows; the Nasdaq Composite recorded 36 new highs and 229 new lows.

Persons: David Lefkowitz, Lefkowitz, Brendan McDermid, Phil Blancato, Ladenburg, John Williams, Lorie Logan, Ryan Cohen, Sinéad Carew, Chuck Mikolajczak, Gertrude Chavez, Dreyfuss, Shristi, Arun Koyyur, Vinay Dwivedi, David Gregorio Our Organizations: Gilead Sciences, Kroger, Dow, Nasdaq, Index, UBS Global Wealth Management, Dow Jones, Monday's Labor, Apple, New York Stock Exchange, REUTERS, Asset Management, York Fed, Dallas, BofA Securities, GameStop, U.S . Securities, Exchange Commission, NYSE, Thomson Locations: Beijing, New York City, U.S, New York, Bengaluru

☆ Bank of America says buy Gilead
▼ + stars: | 2023-09-08 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBank of America says buy GileadThe "Halftime Report" traders debate the biggest analyst calls of the day.

Persons: Gilead Organizations: Email Bank of America

☆ Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America
▼ + stars: | 2023-09-08 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

The biopharmaceutical sector is poised to bounce back this year, and Gilead Sciences could be a key beneficiary, according to Bank of America. Analyst Geoff Meacham upgraded Gilead to buy from neutral. He increased his target price for the stock by $7 to $95, which suggests shares stand to gain 28.5% from where they closed Thursday. Shares of California-based Gilead have dropped 13.9% so far this year. "With the potential for broader interest in the sector, we are more optimistic on performance into 2H23," Meacham said.

Persons: Geoff Meacham, Meacham, biopharma, — Michael Bloom Organizations: Gilead Sciences, Bank of America, PrEP, Kite Pharma Locations: Gilead, California, HCV

☆ Stocks making the biggest moves midday: Kroger, DocuSign, Planet Labs, First Solar and more
▼ + stars: | 2023-09-08 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Kroger earned an adjusted 96 cents per share, beating an LSEG estimate of 91 cents per share. Planet Labs lost an adjusted 14 cents per share on revenue of $53.8 million. Analysts polled by LSEG expected a loss of 8 cents per share on revenue of $54.1 million. DocuSign reported an adjusted 72 cents per share and $688 million in revenue, while analysts polled by LSEG forecast an adjusted 66 cents and $678 million, respectively. First Solar — Shares of the solar panel maker gained 1.4% after Deutsche Bank upgraded the First Solar to buy from hold, citing the company's strong ongoing demand.

Persons: Victor Coleman, Kroger, LSEG, DocuSign, Davidson, Gary Friedman, Gilead, — CNBC's Pia Singh Organizations: Kroger Co, Albertsons Cos Inc, New York Stock Exchange, Hudson Pacific Properties, Hollywood, Avid, Labs, Planet Labs, LSEG, Deutsche Bank, Gilead Sciences, Bank of America Locations: New York City, California

☆ Stocks making the biggest moves before the bell: Kroger, DocuSign, Snowflake, Adobe and more
▼ + stars: | 2023-09-08 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

But the company posted $33.85 billion in quarterly revenue, under the $34.13 billion anticipated by analysts. Planet Labs — The satellite imagery stock slipped 2.6% in premarket trading after delivering a weaker quarterly report than expected on Thursday. DocuSign — The electric signature stock advanced 2.4% premarket on the heels of a stronger-than-expected quarterly report released Thursday. The Wall Street firm said Snowflake is in an advantageous position with "best-in-class growth rates" and is set to benefit from increased demand for artificial intelligence applications. The Wall Street firm cited First Solar's strong growth message during its investors day.

Persons: Kroger, LSEG, DocuSign, Davidson, Snowflake, Mizuho, RH —, Gary Friedman, —, Yun Li, Sarah Min, Jesse Pound, Michelle Fox, Scott Schnipper Organizations: Planet Labs, LSEG, Deutsche Bank, Mizuho, Gilead Sciences, Bank of America Locations: Gilead

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., August 15, 2023. U.S. Treasury yields edged lower on Friday, helping boost major growth stocks, with Microsoft (MSFT.O) leading gains, up 1.9%, and Meta Platforms (META.O) advancing nearly 1%. The S&P 500 information technology (.SPLRCT) sector rose 0.6% while energy stocks (.SPNY) rose 1.3% to their highest level in over seven months, tracking an uptick in crude prices. Advancing issues outnumbered decliners by a 1.64-to-1 ratio on the NYSE and by a 1.01-to-1 ratio on the Nasdaq. The S&P 500 recorded 13 new 52-week highs and 14 new lows, while the Nasdaq posted 31 new highs and 160 new lows.

Persons: Brendan McDermid, Morgan Stanley, Phil Blancato, Ladenburg, John Williams, Lorie Logan, Ryan Cohen, Shristi Achar, Arun Koyyur, Vinay Dwivedi Organizations: New York Stock Exchange, REUTERS, Gilead Sciences, Kroger, Dow, Nasdaq, Apple, Microsoft, Treasury, Wall, Federal Reserve, Index, Federal, Asset Management, FedWatch, New York Fed, Dallas, Dow Jones, BofA Securities, GameStop, U.S . Securities, Exchange Commission, NYSE, Thomson Locations: New York City, U.S, Beijing, Bengaluru

For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents. Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.

Persons: drugmakers, Rebecca Robbins Organizations: Gilead Sciences, The Times

BERLIN, Aug 23 (Reuters) - Roche (ROG.S) inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker's shares even though more data will be needed to confirm the treatment's efficacy. Roche said on Wednesday that market participants had made it aware of the inadvertent disclosure of an interim data analysis on new immunotherapy tiragolumab, part of an experimental class of drugs known as anti-TIGIT. The data lifted Roche shares by 5% and sent shares of other companies testing anti-TIGIT drugs higher. J.P. Morgan analysts said the interim data suggested a survival benefit was within reach in the final analysis, but the clinical relevance remained uncertain. The unintended disclosure regards the second interim analysis of a Phase III trial known as Skyscraper 1.

Persons: Roche, tiragolumab, Morgan, Roche's, TIGIT, Paul Arnold, Christy Santhosh, Jason Neely, Friederike Heine, Mark Potter Organizations: Merck & Co, Gilead Sciences, iTeos Therapeutics, Arcus Biosciences, Thomson Locations: U.S, Zurich, Bengaluru

☆ Gilead Sciences Is the Target of a Bizarre Legal Theory
▼ + stars: | 2023-08-19 | by ( The Editorial Board | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/gilead-sciences-lawsuit-hiv-drug-tdf-taf-pharma-innovation-ef2ea514

Persons: Dow Jones Organizations: pharma Locations: gilead, taf

New York CNN —At least two brands have said they will suspend advertising on X, the platform formerly known as Twitter, after their ads and those of other companies were run on an account promoting fascism. Spokespeople for NCTA and pharmaceutical company Gilead said that they immediately paused their ad spending on X after CNN flagged their ads on the pro-Nazi account. Hours after the Media Matters report was published Wednesday morning and CNN observed additional brands’ ads running on the account, the account appeared to be suspended. “Media Matters and other observers have documented how X has remained a dangerous cesspool of content, especially for advertisers,” Wednesday’s report states. Media Matters says it has also documented instances of brands’ ads being placed next to content from Holocaust denial and white nationalist accounts.

Persons: Linda Yaccarino, Hitler, Gilead, ”, Brian Dietz, ” “, ” Dietz, X, Jason Yellin, NYU Langone, “, Elon, Musk, Yaccarino —, X —, ” Yaccarino, Yaccarino Organizations: New, New York CNN, Media, America, Nazi Party, Adobe, Gilead Sciences, University of Maryland’s, New York University Langone Hospital, Television Association, CNN, ” “ Brand, University of, Maryland Football, NYU, Twitter, CNBC, “ Media, X Locations: New York, Elon Musk’s

☆ Gilead quarterly profit falls on COVID sales drop, legal settlement charge
▼ + stars: | 2023-08-03 | by ( ) www.reuters.com time to read: +2 min

[1/2] Gilead Sciences is seen during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File PhotoCompanies Gilead Sciences Inc FollowAug 3 (Reuters) - Gilead Sciences (GILD.O) on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs. The drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations. Wall Street analysts had expected an adjusted profit of $1.64 per share on revenue of $6.44 billion, according to Refinitiv data. The California-based company raised the low end of its 2023 revenue forecast range to $26.3 billion from $26.0 billion, but kept the high end at $26.7 billion.

Persons: Mike Blake, Gilead, Deena Beasley, Michael Erman, Bill Berkrot Organizations: Gilead Sciences, REUTERS, Wall Street, Thomson Locations: Oceanside , California, U.S, Gilead, California

☆ Trick That Helps Big Pharma Companies Avoid Paying Billons in US Taxes
▼ + stars: | 2023-08-03 | by ( Brad Setser | Tess Turner | ) www.businessinsider.com time to read: +11 min

But take a look at the corporate disclosures of America's largest pharmaceutical companies, and a puzzling hole opens. Large legal loopholesThe offshore migration of these pharmaceutical companies' profits may seem egregious, but the tax gymnastics are generally legal. On paper, America's corporate-tax rate is 21%, but the country's largest and most profitable pharmaceutical companies don't pay anything close to that. What's more, the superlow rate enjoyed by American pharmaceutical companies isn't necessary for these firms to be internationally competitive. A spoonful of medicine to make the taxes go downAmerica's pharmaceutical companies have made great contributions to medicine.

Persons: Democratic Sen, Ron Wyden, AbbVie, it's, Keytruda, Gilead, Eli Lilly, they've, Brad W, Whitney, Tess Turner Organizations: Merck, National Institutes of Health . Pharmaceutical, Democratic, Pfizer, US pharma, US Treasury, Trump, Treasury, US, Denmark's, Nordisk, Novartis, National Institutes of Health, Whitney Shepardson, Council, Foreign Relations Locations: Oregon, America, Caribbean, Europe, Bermuda, Puerto Rico, Germany, Ireland, Singapore, Switzerland, Belgium, Denmark

☆ These are the most overweighted and underweighted stocks by socially conscious funds, according to Bernstein
▼ + stars: | 2023-08-02 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

A handful of the most well-known technology stocks are being somewhat ignored by socially conscious funds, according to Bernstein. Big technology names including Apple , Amazon , Meta , Microsoft and Alphabet were among the most underweighted stocks by North American funds that consider environmental, social and corporate governance factors when screening investment ideas. Big Tech has roared back to life this year, coming off 2022's selloff as investors bet on a better interest rate environment. Here are the 10 most underweighted stocks by North American funds: On the flip side, a wide swath of stocks accounted for the most held, relatively. Barclays analyst Craig Rye said the stock could actually benefit if hurricane season is worse than was previously expected.

Persons: Bernstein, Danaher, Craig Rye, Rye, —, Michael Bloom Organizations: Apple, Meta, Microsoft, North, Big Tech, Software, Nvidia, Insurance, Barclays, Fisher, Deere

☆ On tap this week: Jobs report plus 10 key earnings. Here's what we want to see
▼ + stars: | 2023-07-29 | by ( Zev Fima | ) www.cnbc.com time to read: +18 min

All three major averages advanced for the week, powered by strong mega-cap earnings and favorable inflation data. Looking to next week, earnings season enters its second half with the last of our mega-caps — Apple (AAPL) and Amazon (AMZN) — set to report on Thursday. We'll get a better read on the employment picture on Wednesday with the ADP report and then, more importantly, on Friday's nonfarm payrolls report for July. Thursday after the close brings us to the main events of the week: Earnings from Apple and Amazon. For those looking to review first quarter performance ahead of these releases, be sure to keep our first-quarter earnings report card handy.

Persons: We'll, that's, Stanley Black, Decker, Emerson, Bausch, Leggett, Platt, SIRI, Ares, COLM, PERI, Kraft Heinz, Phillips, Ferrari N.V, Johnson, Robinson, COOK, BUD, Kellogg, Papa, Pitney Bowes, Parker, Trimble, Ziff Davis, Nonfarm, Jim Cramer's, Jim Cramer, Jim, Apple Tim Cook, Kevin Dietsch Organizations: Nasdaq, Dow, Federal Reserve, Federal, ISM Manufacturing, Services PMI, Investors, Caterpillar, Devices, Starbucks, Natural Resources, AMD, Management, Emerson Electric and, Humana, Bausch Health, Apple, Microsoft, Resource Partners, AerCap Holdings, CNA Financial Corp, CNA, Apellis Pharmaceuticals, Bank, SJW, Hutchison China MediTech, Camtek Ltd, Silvercrest Asset Management, Loews Corp, Oxford Lane Capital Corp, Banco Santander, Silicom Ltd, SuperCom Ltd, Arista Networks, Avis Budget Group, Diamondback Energy, Lattice Semiconductor Corp, Republic Services, Yum China Holdings, Western Digital Corp, Power Systems, Tenet Healthcare Corp, Vornado Realty, BioMarin Pharmaceutical, PetMed, SBA Communications Corporation, Brixmor, Snack Foods Corp, Cushman & Wakefield, Sanmina Corporation, TFI, PMI, Cruise Line Holdings Ltd, Uber Technologies, Pfizer, Enterprise Products Partners, Merck, JetBlue Airways Corporation, Allegro MicroSystems, Altria, SunPower Corp, SiriusXM Holdings, Molson Coors Beverage, Marriott International, Toyota Motor Corp, BP, SYSCO Corp, Marathon Petroleum Corp, Ares Management, Equitrans Midstream Corporation, Game Technology, Illinois Tool, IDEXX Laboratories, Rockwell Automation, Packaging International Corp, Gartner, Zebra Technologies Corp, IQVIA Holdings, Oshkosh Corporation, Leidos Holdings, Eaton Corp, yte Corp, Lear Corp, Starbucks Corp, Devon Energy Corp, SolarEdge Technologies, Lumen Technologies, Virgin Galactic Holdings, Caesars Entertainment, VF Corp, Sciences Corp, Paycom, Vertex Pharmaceuticals, Suncor Energy, Holdings, Chesapeake Energy Corp, Boston Properties, American International Group, AIG, Allstate Corp, Aspen Technology, Electronic Arts, EA, Flowserve Corporation, Denny's, Corp, Prudential Financial, Store, Ternium S.A, Vimeo, Emerson, Lomb, CVS Health, Generac Holdings, Cameco Corp, Perion Network Ltd, Builders, Carlyle Group, Scorpio, Teva Pharmaceutical Industries, Ltd, Rithm Capital Corp, AeroSystems Holdings, Vertiv Holdings Co, Johnson Controls, CDW Corp, DuPont, Brands Holdings, Scotts Miracle, Gro, SMG, Brands, Allegheny Technologies, AmerisourceBergen Corporation, ABC, Real Estate Corporation, Adient plc, Editas, Garmin Ltd, WWE, Bunge Ltd, Criteo S.A, PayPal, QUALCOMM, Occidental Petroleum Corp, Apache Corp, Albemarle Corp, MGM Resorts International, MGM, Marathon Oil Corp, Joby Aviation, Industrial, CF Industries Holdings, Goodyear Tire &, Realty ome Corp, Metlife, Pacific Biosciences of, Rush Street Interactive, Zillow, JFrog Ltd, Herbalife Nutrition Ltd, Simon Property Group, McKesson Corp, Storage, Cerus Corporation, GXO Logistics, MAX Holdings, Health, Anheuser, Busch InBev, Warner Bros ., Cheniere Energy, ConocoPhillips, Hasbro, CIGNA Corp, Lantheus Holdings, Regeneron Pharmaceuticals, Fiverr International, Air Products & Chemicals, TopBuild Corp, EPAM Systems, Lightspeed Commerce, Aurinia Pharmaceuticals, Cummins, CMI, Slair Corporation, Starwood Property Trust, Vulcan, Alnylam Pharmaceuticals, New Energy Corp, Cedar Fair Entertainment, Intellia Therapeutics, Lending, Privia Health, Dickinson, Chimera Investment, CIM, Hyatt Hotels Corp, Lion Electric, LEV, Deluxe Corp, Murphy Oil Corp, PBF Energy, Papa John's, Targa Resources Corp, Wix.com Ltd, Apollo Global Management, LLC, Butterfly, Sempra Energy, Aptiv PLC, Brookfield Infrastructure Partners, Canada Goose Holdings, Hannifin Corporation, WESCO International, WCC, Arrow Electronics, Constellation Energy Group, Midstream Partners, Coinbase, Petroleo Brasileiro SA Petrobras, Gilead Sciences, Opendoor Technologies, Booking Holdings, Atlassian Corporation, International, Redfin Corporation, Motorola Solutions, Monster Beverage Corporation, Consolidated Edison, Rocket Companies, Apple Hospitality, Cirrus, Resources, Universal Display Corporation, Chesapeake Utilities Corp, Social, Defense, Security Solutions, Post Holdings, Tandem Diabetes Care, Nikola Corporation, Magna International, Dominion Energy, ACM Research, Frontier Communications, Brookfield Renewable Partners, inTEST Corporation, American Pipeline, TELUS International, XPO Logistics, Fluor Corp, Gray Television, Cboe, LyondellBasell Industries, Twist Bioscience, Global, Jim Cramer's Charitable, CNBC, Allen & Company Sun Valley, Getty Locations: U.S, China, India, Oxford, Chile, Illinois, Columbia, Pacific, Pacific Biosciences of California, Southern, PBI, Gilead, Sun Valley , Idaho

☆ Stocks making the biggest moves midday: AMC Entertainment, Mattel, Chevron, Spotify and more
▼ + stars: | 2023-07-24 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +4 min

Knight-Swift Transportation — The freight transportation company's shares gained more than 1%. Knight-Swift reported adjusted earnings of 49 cents per share on revenue of $1.55 billion. Intuitive Surgical reported adjusted earnings of $1.42 per share on revenue of $1.76 billion. The fast-food chain reported mixed quarterly results, including adjusted earnings of $3.08 per share, beating analysts' predictions for $3.05 per share. Spotify — The music streaming company's shares dropped 5.5% after Spotify announced price increases for its premium subscription plans.

Persons: Oppenheimer, Riley, Eric Wold, Barbie, Mike Wirth, Chevron, Swift, Domino's, Becton Dickinson, Raymond James, Gilead, Estée Lauder, Piper Sandler, — CNBC's Hakyung Kim, Yun Li, Alex Harring, Samantha Subin Organizations: AMC, Mattel, Warner Bros, Chevron, Swift Transportation, U.S . Food, Drug Administration, Sirius XM, Deutsche Bank, Nasdaq, Spotify, Gilead Sciences Locations: New York, U.S, Gilead, China

The promising drug, then in the early stages of testing, was an updated version of tenofovir. The “patent extension strategy,” as the Gilead documents repeatedly called it, would allow the company to keep prices high for its tenofovir-based drugs. Gilead could switch patients to its new drug just before cheap generics hit the market. By putting tenofovir on a path to remain a moneymaking juggernaut for decades, the strategy was potentially worth billions of dollars. The delayed release of the new treatment is now the subject of state and federal lawsuits in which some 26,000 patients who took Gilead’s older H.I.V.

Persons: Gilead

Companies Gilead Sciences Inc FollowJuly 21 (Reuters) - Gilead Sciences Inc (GILD.O) said on Friday it was stopping a late-stage trial of its blood cancer combination treatment following an analysis that showed it would not be effective. Gilead, whose shares dropped over 1% in after-market trading, recommended that treatment with magrolimab in patients with MDS should be stopped. The company gained access to magrolimab with its $4.9 billion buyout of Forty Seven Inc in March 2020. Magrolimab is also in development for other types of cancer such as acute myeloid leukemia and solid tumours. Reporting by Sriparna Roy in Bengaluru Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

Persons: Gilead, Robert W, Baird, Brian Skorney, Magrolimab, Sriparna Roy, Vinay Dwivedi Organizations: Gilead Sciences, Gilead Sciences Inc, Seven Inc, Thomson Locations: Bengaluru

That compares with a 14.8% gain for the benchmark S&P 500 (.SPX). Microsoft (MSFT.O), Apple (AAPL.O), Nvidia (NVDA.O), Amazon.com (AMZN.O) and Tesla (TSLA.O) combined account for 43.8% weight in the index, according to Refinitiv data as of Monday's close. The special rebalancing may be conducted at any time if the aggregate weight of companies, each having more than 4.5% weight in the index, tops 48%, according to Nasdaq. COULD THE S&P 500 FOLLOW SUIT? Apple and Microsoft are the only two firms with weight over 4.5% in the S&P 500.

Persons: Hogan, Cameron Lilja, Dow, Wells, Sam Stovall, Sruthi Shankar, Medha Singh, Bansari, David Randall, Shounak Dasgupta Organizations: Nasdaq, Microsoft, Apple, Nvidia, Riley, U.S . Securities, Exchange, Dow Jones, Tesla, Booking Holdings, Gilead Sciences, Devices, CFRA, Thomson Locations: Wells, Gilead, Bengaluru, New York

July 3 (Reuters) - AstraZeneca (AZN.L) said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped. It declined to provide more trial details, saying they would be presented at an as yet undisclosed medical conference. At 0855 GMT, shares in AstraZeneca were down 5.8% at their lowest level in more than three months. Gilead (GILD.O) has pioneered the targeting of TROP2 with an ADC named Trodelvy, approved to treat certain types of breast and bladder cancer. AstraZeneca said that the datopotamab deruxtecan trial would continue as planned to assess the effect of the drug on overall survival of patients, another important efficacy criterion.

Persons: datopotamab, AstraZeneca, British drugmaker, Kelun, Maggie Fick, Ludwig Burger, Sinchita Mitra, Lucy Raitano, Krishna Chandra Eluri, Susan Fenton Organizations: AstraZeneca, Japan's, Merck & Co, Biotech of, Barclays, Thomson Locations: British, Biotech of China, London, Frankfurt, Bengaluru

☆ Hepatitis C cure is not reaching overwhelming majority of patients due to financial barriers
▼ + stars: | 2023-06-29 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

Hepatitis C is often referred to as the silent killer because the initial infection has few to no symptoms. Overtime, however, the virus can cause liver damage, liver cancer, liver failure and ultimately death. These pills, taken once a day for eight to 12 weeks, cure more than 95% of hepatitis C cases. Hepatitis C contributed to the deaths of nearly 15,000 people in 2020, according to the CDC. The Biden administration has asked Congress to approve $11 billion in funding for a national program to eliminate hepatitis C by 2030.

Persons: Dr, Jonathan Mermin, Biden, Francis Collins Organizations: Gilead Sciences, U.S ., Centers for Disease Control, Health, CDC, White Locations: U.S

Search resuls for: "Gilead"

25 mentions found